#United States #Boston #Biopharma #SOPHiA GENETICS #AI-driven medicine

SOPHiA GENETICS Reports Q3 Financial Results

In a notable development, SOPHiA GENETICS (Nasdaq: SOPH), a leading player in AI-powered precision medicine, disclosed its financial performance for the third quarter of 2026. The results reflect considerable growth and resilience despite challenges in the global market.

Financial Overview

During the third quarter ending September 30, 2026, SOPHiA GENETICS recorded revenues amounting to $24.3 million, marking a 25% increase compared to the same period last year. This growth rate underscores the company’s robust trajectory as it continues to adapt to industry demands and opportunities.

The gross margin was reported at 65.7% on a reported basis and 72.8% when adjusted for certain costs. These figures reflect a slight decline from the previous year, which had gross margins standing at 66.3% and 73.1%, respectively. Although the company faced a net loss of $20.3 million—an increase of just 1% from the previous year—its adjusted EBITDA loss significantly improved by 31%, reducing it to $6.1 million. This improvement indicates a positive trajectory toward operational efficiency and potential profitability.

CEO Ross Muken expressed optimism about the results, stating, "Record analysis volumes, strong performance in the U.S. market, and increasing momentum in BioPharma led to another outstanding quarter. The growth in revenue by 25% year-over-year exemplifies the scalability of our AI-driven platform."

Strategic Partnerships and Growth Areas

SOPHiA GENETICS highlighted significant milestones in expanding its market footprint. The company signed 30 new genomics customers in Q3 and closed three significant BioPharma agreements that include two companion diagnostic programs and a groundbreaking multimodal AI collaboration aimed at enhancing treatment for bladder cancer patients.

The successful growth in revenue was particularly noticeable in both North America and Asia Pacific, where revenue grew by 45% and 33% year-over-year, respectively. A noteworthy achievement during this period was the performance of SOPHiA DDM™, which saw a record 118,000 analyses conducted, showcasing a 19% year-over-year increase in analysis volume.

The U.S. market proved to be a significant contributor, with 41% year-over-year revenue growth. Strategic signings, including contracts with notable healthcare institutions like the University of North Carolina and King Chulalongkorn Memorial Hospital, position SOPHiA for continued growth in emerging treatment areas such as Rare Disorders and Solid Tumors.

Future Outlook

Looking further ahead, SOPHiA GENETICS anticipates that the total revenue for the full year will align with the higher end of its previously set guidance range of $94 million to $96 million. This optimistic outlook is tempered by the potential impacts of foreign exchange rates, which the company acknowledges could serve as a headwind in the final quarter of 2026.

Muken elaborated on the company’s strategy: "Our expanding presence in new geographic markets, the introduction of innovative products, and nurturing our relationships with BioPharma partners are expected to fuel significant growth opportunities."

The company also reaffirms its commitment to achieving a positive adjusted EBITDA in the latter half of 2027. This commitment to operational excellence and investment in cutting-edge technologies highlights SOPHiA GENETICS' dedication to enhancing patient care through improved data access and analytics.

As SOPHiA GENETICS prepares for an upcoming conference call on November 3, 2026, to further discuss its financial results, stakeholders remain optimistic about the company's potential to navigate the complexities of the precision medicine landscape successfully. For those following SOPHiA GENETICS, these developments signal a bright path forward driven by innovation and strategic partnerships in the healthcare sector.